1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Novo's Oral Semaglutide Passes PIONEER 2, But Weight Loss Result A Bit Disappointing

 
• By Emily Hayes

In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.

Diabetes-Concept_56048224_1200x675

Novo Nordisk AS's once-daily, oral version of the GLP-1 agonist semaglutide demonstrated superior blood sugar lowering in the Phase III PIONEER 2 study, which tested the drug against Eli Lilly & Co./Boehringer Ingelheim GMBH's SGLT-2 inhibitor Jardiance (empagliflozin), while falling a bit short on weight loss and carrying nausea as a common side effect.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

Arbele Leverages Rights As It Drugs Proprietary CDH17 Target

 
• By Dexter Jie Yan

Arbele has emerged as a global leader in the Cadherin 17 area, not only in clinical progress but also for its “secret recipe” for application in T-cell engagers, its CEO tells Scrip.

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

 
• By Jessica Merrill

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

More from R&D

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

China’s Biotech Stocks Proved More Resilient Than US’s Amid Market Turmoil

 
• By Andrew McConaghie, Edwin Elmhirst, and Dexter Jie Yan

Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.